Role of Polymeric Excipients on Controlled Release Profile of Glipizide from PLGA and Eudragit RS 100 Nanoparticles

Naha, Pratap C.; Byrne, Hugh J.; Panda, Amulya K.

doi:10.1166/jnd.2013.1005

Cited by 18 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As far as we know, methacrylic acid and methyl methacrylate-based polymers cellular effects have been studied on different cellular lines, on human hepatoma cell line (HepG2) [40], adenocarcinoma cell line of the human colon cells (SW480) [41], fibroblast cells (NIH/3T3) [42], with no adverse cytotoxicity effects shown. In fact, Eudragit is included in the FDA Inactive Ingredients Guide [43].…”

Section: Resultsmentioning

confidence: 99%

Targeted Release of Probiotics from Enteric Microparticulated Formulations

Gracia

Larrea

et al. 2019

Polymers

View full text Add to dashboard Cite

The development of advanced probiotic delivery systems, which preserve bacteria from degradation of the gastrointestinal tract and achieve a targeted release mediated by pH-independent swelling, is of great interest to improve the efficient delivery of probiotic bacteria to the target tissue. Gram-positive and Gram-negative bacteria models (Lactobacillus acidophilus (Moro) Hansen and Mocquot (ATCC® 4356™) and Escherichia coli S17, respectively) have been successfully encapsulated for the first time in pH-independent microparticulate polymethacrylates (i.e., Eudraguard biotic) used for the targeted delivery of nutraceuticals to the colon. These bacteria have also been encapsulated within the mucoadhesive polymethacrylate Eudragit RS 100 widely used as targeted release formulation for active pharmaceutical ingredients. The enteric microparticles remained unaltered under simulated gastric conditions and released the contained viable microbial cargo under simulated intestinal conditions. Buoyancies of 90.2% and 57.3% for Eudragit and Eudraguard microparticles, respectively, and long-term stability (5 months) for the encapsulated microorganisms were found. Cytotoxicity of the microparticles formulated with both polymers was evaluated (0.5–20 mg/mL) on Caco-2 cells, showing high cytocompatibility. These results underline the suitability of the synthesized materials for the successful delivery of probiotic formulations to the target organ, highlighting for the first time the potential use of Eudraguard biotic as an effective enteric coating for the targeted delivery of probiotics.

show abstract

Section: Resultsmentioning

confidence: 99%

Targeted Release of Probiotics from Enteric Microparticulated Formulations

Gracia

Larrea

et al. 2019

Polymers

View full text Add to dashboard Cite

show abstract

“…The relationship between the formulation variables and the responses in terms of coded factors is represented by the following equations [29, 30].…”

Section: Resultsmentioning

confidence: 99%

Preparation, Optimization and In vitro Evaluation of Glipizide Nanoparticles Integrated with Eudragit RS-100

Saharan

Bahmani

Saharan

2019

PNT

View full text Add to dashboard Cite

Background: Solubility is an important criterion for drug efficacy, independent of the route of administration. It also poses a major challenge for pharmaceutical industries, which are developing new pharmaceutical products, since 40% of the active substances being identified are either insoluble or poorly soluble in aqueous media. Objective: The objective of this study was to develop nanoformulation of glipizide drugloaded nanoparticles providing controlled release formulation. Method: Nanoparticles were prepared by the solvent evaporation method. Eudragit RS100, a nonbiodegradable polymer with varying ratios was used for making the formulation. The effect of key formulation variables on the particle size and entrapment efficiency and drug loading of nanoparticles were studied by using factorial design. Results: DSC thermograms indicate that glipizide was dispersed in an amorphous state in the polymer. TEM study indicates that the nanoparticles were in spherical shape. The mean diameter was dependent on the presence of the amount of Eudragit RS100 and viscosity of the organic phase. The in vitro study showed that the cumulative drug release was from 69.52-81.44 % in 10 hrs at pH 6.8 in phosphate buffer respectively. Conclusion: Conclusion: The developed NPs could reduce dose frequency, decrease side effects, and improve patient compliance. Using factorial design, maximum entrapment efficiency with minimum particle size could be achieved with a few experiments.

show abstract

“…94,95 PLA- and PLGA-based nanocarriers were developed to deliver various drugs; 96,97 however, the rapid burst of cargo release without any specificity limited further in vivo application due to the low drug concentration at the desired site. 98,99 Thus, subsequent work focused on improving the specific release of drugs at the disease site by linking drug release with a specific biological process.…”

Section: Organic Nanoscale Materials Employed For Pharmaceutical Devementioning

confidence: 99%

Biosafe Nanoscale Pharmaceutical Adjuvant Materials

Jin¹,

Li²,

Wang³

et al. 2014

j biomed nanotechnol

View full text Add to dashboard Cite

Thanks to developments in the field of nanotechnology over the past decades, more and more biosafe nanoscale materials have become available for use as pharmaceutical adjuvants in medical research. Nanomaterials possess unique properties which could be employed to develop drug carriers with longer circulation time, higher loading capacity, better stability in physiological conditions, controlled drug release, and targeted drug delivery. In this review article, we will review recent progress in the application of representative organic, inorganic and hybrid biosafe nanoscale materials in pharmaceutical research, especially focusing on nanomaterial-based novel drug delivery systems. In addition, we briefly discuss the advantages and notable functions that make these nanomaterials suitable for the design of new medicines; the biosafety of each material discussed in this article is also highlighted to provide a comprehensive understanding of their adjuvant attributes.

show abstract

Role of Polymeric Excipients on Controlled Release Profile of Glipizide from PLGA and Eudragit RS 100 Nanoparticles

Cited by 18 publications

References 31 publications

Targeted Release of Probiotics from Enteric Microparticulated Formulations

Targeted Release of Probiotics from Enteric Microparticulated Formulations

Preparation, Optimization and In vitro Evaluation of Glipizide Nanoparticles Integrated with Eudragit RS-100

Biosafe Nanoscale Pharmaceutical Adjuvant Materials

Contact Info

Product

Resources

About